Journal
PHARMACOTHERAPY
Volume 42, Issue 7, Pages 585-589Publisher
WILEY
DOI: 10.1002/phar.2706
Keywords
adverse event; calcitonin gene-related peptide; case report; drug safety; migraine disorder; pharmacovigilance
Categories
Ask authors/readers for more resources
This article reports a case of myocardial infarction associated with erenumab treatment. Further research is needed to assess the risk of myocardial infarction in patients treated with CGRP-mab, especially in patients over the age of 40. When assessing cardiovascular risk, individual risk factors should be taken into account, and appropriate examinations should be conducted if necessary.
Background Monoclonal antibodies acting on the calcitonin gene-related peptide or its receptor (CGRP-mabs) are novel drugs for resistant migraine prophylaxis. As CGRP-mabs cause inhibition of vasodilatation, their use is reserved to patients with no recent history of cardiovascular diseases. We report a case of myocardial infarction associated with erenumab. Case A 57-year-old woman with a familial history of coronaropathy was first treated with erenumab 70 mg for 6 months and then increased to 140 mg. Almost 5 months after, the patient presented chest pain, increased troponin, and abnormal electrocardiogram. A myocardial infarction without coronarography abnormality was diagnosed through MRI. Conclusion Further evidence is needed to assess the risk of myocardial infarction in patients treated with a CGRP-mab. In patients over 40 years of age, the risk of coronary or cardiovascular events should be assessed using risk tables or algorithms to take into account cardiovascular risk factors. This may be complemented by appropriate examinations to measure the burden of coronary atherosclerosis, if necessary.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available